Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Frailty × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Glioblastoma 230 Glioma 94 Brain Neoplasms 86 Gliosarcoma 77 Astrocytoma 56 Central Nervous System Neoplasms 54 Oligodendroglioma 40 Melanoma 35 Neuroblastoma 23 Recurrence 18 Medulloblastoma 15 Ependymoma 15 Neoplasms 14 Neoplasm Metastasis 14 Sarcoma, Ewing 12 Lymphoma 10 Diffuse Intrinsic Pontine Glioma 10 Sarcoma 9 Rhabdomyosarcoma 9 Neuroendocrine Tumors 9 Lung Neoplasms 8 Unspecified Adult Solid Tumor, Protocol Specific 6 Small Cell Lung Carcinoma 5 Osteosarcoma 5 Optic Nerve Glioma 5 Neuroectodermal Tumors, Primitive 5 Colorectal Neoplasms 5 Choroid Plexus Neoplasms 5 Breast Neoplasms 5 Wilms Tumor 4

Interventions

Geriatric Assessment 9 Preoperative Exercise 3 Standard of Care 2 Observation 2 Nutritional Support 2 Exercise 2 peflavit 1 microcrystalline cellulose 1 fisetin 1 epigallocatechin gallate 1 diacetamate 1 cabozantinib 1 Ultrasonography 1 Tretinoin 1 Therapeutics 1 Temozolomide 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Spectroscopy, Near-Infrared 1 Restraint, Physical 1 Quercetin 1 Qigong 1 Psychosocial Intervention 1 Protons 1 Photons 1 Nutrition Assessment 1 Methods 1 Immunonutrition Diet 1 Flavonoids 1 Enhanced Recovery After Surgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡